Background
==========

Description of the Condition
----------------------------

Influenza (the flu) is an acute infection of the upper respiratory tract which is transmitted via respiratory droplets and direct contact. Immunocompromised people and those with underlying cardio-pulmonary conditions are considered at increased risk from serious influenza-related complications. Annually, influenza infection results in more than 500, 000 deaths worldwide \[[@B1]\]. The influenza virus is an RNA virus that belongs to the Orthomyxoviridae family \[[@B2]\]. There are two main types of influenza virus: type A and type B \[[@B2]\]. These two types are responsible for seasonal flu epidemics each year. The influenza virus is continually evolving and under immune pressure; it may either evolve through small gradual changes in the virus (antigenic drift) or through abrupt major changes in the virus (antigenic shift) most frequently by genetic reassortments \[[@B3]\]. Such changes can result in the emergence of new influenza viruses that can cause pandemics (e.g., the 1918 Spanish flu pandemic and the 2009 H1N1 pandemic)\[[@B4]\].

Description of the interventions
--------------------------------

Vaccines play a critical role in the prevention of influenza \[[@B5]\]. Nevertheless, the efficacy of this intervention could be significantly reduced owing to a mismatch between the seasonal influenza vaccine and the circulating influenza virus and the inability of the host to mount a proper immune response \[[@B6]\]. Therefore, antivirals also play an important role in the prevention and management of influenza. There are two classes of antiviral agents for influenza: adamantanes and neuraminidase inhibitors. Adamantanes (amantadine and rimantadine), however, are not recommended alone for the treatment of influenza due to their lack of activity against influenza B and the high level of influenza A resistance \[[@B6],[@B7]\]. Neuraminidase inhibitors (NAIs) are effective against all human, avian and animal influenza viruses \[[@B6]-[@B8]\]. NAIs inhibit the release of virions by competitively inhibiting viral NA, which is a key glycoprotein at the surface of the virus. Currently there are two NAIs drugs which have been approved worldwide: Oseltamivir (Tamiflu^®^) and Zanamivir (Relenza^®^). Both drugs are approved for treatment of acute uncomplicated illness due to influenza A and B, and are also approved for preventive use \[[@B9]\]. Oseltamivir is provided orally to persons older than one year who have been symptomatic for no more than 2 days \[[@B9]\]. Zanamivir is provided as a dry powder which is given by inhalation in persons aged 7 years and older who have been symptomatic for no more than 2 days \[[@B9]\].

Peramivir is an intravenous neuraminidase inhibitor under development for the treatment of influenza. In October 2009, the FDA issued an Emergency Use Authorization (EUA) for the use of peramivir based on safety data from Phase 1, Phase 2 trials, and limited Phase 3 trial data. The EUA for peramivir expired in June 2010. However, peramivir has been approved in Japan and Korea. More recently, laninamivir, a long-lasting inhaled neuraminidase inhibitor has also been licensed in Japan \[[@B10],[@B11]\].

Antiviral resistance
--------------------

Influenza A and B strains had remained susceptible to oseltamivir with rare exceptions since their availability in 1999. Recent reviews and expert opinions have identified studies reporting prevalence and incidence rates of antiviral resistance among patients treated with oseltamivir \[[@B6],[@B7]\]. Until recently, the prevalence of antiviral resistance had been relatively low \[[@B12],[@B13]\]. However, in the influenza season 2008-2009, the Centers for Disease Control and Prevention (CDC) reported a worldwide significant increase in the prevalence of oseltamivir resistance to influenza A/H1N1 viruses (A/Brisbane/59/2007-like strains) due to the H275Y NA mutation \[[@B9]\]. Furthermore, about 1% of tested 2009 pandemic H1N1 viruses (A/California/07/2009 (H1N1) - like strain) were found to be resistant to oseltamivir due to the same mutation. Finally, a Japanese study published in 2004 reported incidence of antiviral resistance in hospitalized children as high as 18%\[[@B14]\].

To date influenza A and B, including all types of A/H1N1 virus, remain susceptible to zanamivir. Further, a recent review only found one documented case of zanamivir resistance \[[@B6],[@B15]\]. Oseltamivir is easier to administer and has therefore been used vastly more than zanamivir. For this reason, most literature on antiviral resistance associated with NAIs has only investigated antiviral resistance associated with oseltamivir. However, owing to the higher resistance rates associated with oseltamivir, especially for A/H1N1 strains between 2007-09, zanamivir has been increasingly utilized for the treatment and prevention of influenza \[[@B9]\]. Therefore, there is a need to investigate the development of influenza resistance to zanamivir in this time period. Studies investigating resistance to peramivir may also have emerged.

We therefore conducted a systematic review using comprehensive literature search strategies to identify and systematically assess all relevant studies on antiviral resistance associated with oseltamivir, zanamivir, and peramivir.

Objectives
==========

Primary objective
-----------------

Our primary objective was to systematically review the literature to determine the incidence of resistance to oseltamivir, zanamivir, and peramivir in adult immunocompetent outpatients for the prevention and treatment of influenza. We did not consider lananimivir since it was not licensed at the time we commenced this review.

Secondary objectives
--------------------

Our secondary objectives were to

1\) Systematically review data from the literature to determine the incidence of resistance to oseltamivir, zanamivir, and peramivir in different patient populations (e.g., hospitalized, immunocompromised, children, and others).

2\) Assess the clinical consequences of antiviral resistance (clinical complications and symptoms associated with antiviral resistance, and severity of complications and symptoms among resistant patients).

Methods
=======

Criteria for considering studies for this review
------------------------------------------------

### Types of studies

We included randomized clinical trials (RCTs), cohort and case-control studies, and case reports.

### Types of patients

We included adult immunocompetent outpatients for our primary objective. For our secondary objective we included patients if they were children, immunocompromised, or hospitalized.

### Types of interventions

We included studies that reported incidence of antiviral resistance associated with one or more of the three NAIs oseltamivir, zanamivir, and peramivir. We included all studies regardless of the dose and length of follow-up. We did not include studies where an NAI was administered in combination with another antiviral (e.g., rimantadine)

### Types of outcomes

Our primary and first secondary outcome of interest was incidence of antiviral resistance and our secondary outcomes of interest were the clinical consequences associated with antiviral resistance.

Viral resistance is detected either by the presence of resistance-associated mutations such as the H274Y (N2 numbering) or H275Y (N1 numbering) substitution or by measuring the median 50% inhibitory concentration (IC~50~). Commonly used laboratory criteria for determining known antiviral resistance is a substantially elevated IC~50~value by enzyme inhibition assay (a value greater than 10-fold that of the corresponding parent virus or greater than three standard deviation (SD) compared to the mean value \[[@B13],[@B16]\]. For example, for the H1N1 virus with the most frequent H275Y NA mutation, the observed IC50 values are usually 200- 400 fold higher than the mean IC50 value \[[@B17]-[@B21]\]. However, the definition of antiviral resistance is not standardized and could differ for each of the three NAIs, and may also vary across included studies (due to pre-specification of a threshold or different assays). For that reason, we used the definition of resistance as outlined in the studies to determine the incidence of antiviral resistance.

Measured influenza outcomes included duration of antiviral shedding, the peak viral titers, and the days to resolution of influenza symptoms. For studies reporting on clinical consequences of antiviral resistance, we reported all influenza related complications and symptoms.

Electronic searches and data retrieval
--------------------------------------

We searched MEDLINE and EMBASE without language restrictions in September 2010. We limited the search strategy to human studies. We also manually searched reference lists from recent review articles.

### Study selection and Data Extraction

Two reviewers (KT and TA) independently reviewed the abstracts for potential eligibility and subsequently full text publications for eligibility. Disagreements were resolved by discussion.

We extracted a number of variables on study design and methodological characteristics, patient and intervention characteristics, and outcomes from all eligible studies (see appendix). Data extraction was done independently by two reviewers (KT and TA) and disagreements were resolved by discussion.

Methodological Quality Assessment
---------------------------------

For the RCTs, we assessed the adequacy of the methods used for randomization, allocation concealment, blinding, and follow-up \[[@B22],[@B23]\]. We scored the quality for each RCT by assigning one point for each adequate item. With this scale, RCTs can score a minimum of 0 points and a maximum score 4 points. We considered RCTs that scored at least 3 points as high quality. We used the Newcastle-Ottawa Scale (NOS) to assess the adequacy of the employed methodology in the retrieved observational studies \[[@B24]\]. For observational studies reporting incidence of antiviral resistance, there were no control groups. We therefore used a modified version of the NOS scale for cohort studies, taking out the three items that dealt with adequacy of controls or comparison between exposed and non-exposed individuals. With this scale, incidence studies can score a minimum of 0 points and a maximum of 6 points. We considered studies that scored at least 5 points as high quality. For observational studies reporting on consequences of antiviral resistance, we used the complete NOS scale. With this scale, incidence studies can score a minimum of 0 points and a maximum of 9 points. We considered studies that scored at least 7 points as high quality.

Statistical analysis and reporting of results
---------------------------------------------

We calculated the antiviral resistance incidence rate and the associated 95% confidence interval (CI) for all studies and study subgroups. Antiviral resistance incidence rate was calculated as the proportion of patients who developed resistance. We calculated the 95% CI based on the assumption that the incidence rate followed a binomial distribution. For incidence rates equal to 0%, we used the \"rule of threes\" to calculate the upper 95% CI upper bound \[[@B25]\]. This rule says that the 95% CI upper bound is equal to 3/n, where n is the sample size.

Primary objective - estimating incidence
----------------------------------------

We calculated the antiviral resistance incidence rate and the associated 95% CI for all studies (and subgroups) involving immunocompetent adult out-patients. We produced forest plots and pooled incidence rates across studies using the arcsine method \[[@B26]\].

Secondary objective - incidence across subgroups
------------------------------------------------

We first performed subgroup analysis on type of NAIs (oseltamivir, zanamivir, or peramivir) and pooled incidence rates within each subgroup using the arcsine method \[[@B26]\]. For each type of NAIs, we then performed subgroup analyses for study design, type of influenza, immunocompetent/immunocompromised patients, out patients/hospitalized patients, adults/children, and prophylaxis/treatment and produced corresponding forest plots. We did not produce pooled estimates in these subgroups.

Secondary objective - consequences of antiviral resistance
----------------------------------------------------------

We qualitatively compared the mean, median, minimum, and maximum duration of antiviral shedding, the peak viral titers, and the days to resolution of influenza symptoms reported in the identified incidence studies.

We reported odds ratios and risk ratios for associations between antiviral resistance and clinical complications or symptoms. Whenever possible, these ratios were combined in a random-effects meta-analysis and presented in a forest plot. Adjusted ratios obtained from multivariate models were preferred to crude ratios. If possible, risk ratios were converted to odds ratios.

For resistant patients reported in case reports, we created a qualitative overview (a table) of clinical complications (e.g., pneumonia) and symptoms which authors believed could be associated with resistance.

Results
=======

Our search resulted in 1289 hits after removal of duplicate citations. Figure [1](#F1){ref-type="fig"} presents the PRISMA diagram for our eligibility scan. A total of 43 study reports were eligible. Among these, ten were randomized clinical trials (RCTs) that reported incidence of antiviral resistance,\[[@B27]-[@B36]\] (effectively fourteen since two publications reported results from four and three RCTs respectively) and nine were cohort studies that reported incidence of antiviral resistance \[[@B14],[@B37]-[@B44]\]. Four were case-control studies that reported associations between antiviral resistance and clinical symptoms or complications \[[@B45]-[@B48]\]. Lastly, 21 were case reports comprising reports on a total of 27 patients \[[@B15],[@B49]-[@B68]\]. None of the ten RCTs or the nine cohort studies made head to head comparisons between any two of the three NAIs (i.e., all 19 studies only included one NAI arm). Thirteen studies measured incidence of antiviral resistance among subjects given oseltamivir,\[[@B14],[@B31],[@B33],[@B35],[@B37]-[@B44]\], five studies measured incidence of antiviral resistance among subjects given zanamivir,\[[@B27],[@B29],[@B30],[@B32],[@B34]\] and only one study measured incidence of antiviral resistance among subjects given peramivir \[[@B28]\]. Four oseltamivir studies and all zanamivir and peramivir studies were RCTs. The four association studies all estimated associations between oseltamivir resistance and clinical complications and symptoms. Among the 21 case reports, 17 reported on resistance to oseltamivir only, and 2 on resistance to zanamivir only, and 2 on resistance to both. In 12 of the 21 case reports (13 out of 27 patients) where oseltamivir was the initial treatment, patients were eventually switched to zanamivir.

![**PRISMA diagram of literature search and eligibility scan**. Study reports were excluded if 1) they were expert opinions, commentaries, letters or reviews; 2) if it was clear that they did not include either oseltamivir, zanamivir, or peramivir treated patients; or 3) if it was clear that none of the considered outcomes could be extracted.](1471-2334-11-134-1){#F1}

Most studies that reported incidence of antiviral resistance included a mix of our pre-specified subgroups. The methodological quality, the patient characteristics, and the intervention characteristics of the incidence studies are presented in table [1](#T1){ref-type="table"}. All RCTs were of high quality. Only one incidence study was low quality according to the modified NOS. The four case-control studies that reported associations between antiviral resistance and clinical symptoms and complications all scored between 7/9 and 9/9 on the NOS.

###### 

Baseline characteristics of studies reporting on incidence of resistance

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                            Study   Intervention   Patients                                                                                                                                                    
  --------------------------- ------------- ------- -------------- -------------- ---------------------------------------------------------------------------------------------------- --------------- ------------- --------- ----------
  ***Zanamivir studies***                                                                                                                                                                                                      

  Boivin^31^\                 1997-1998     RCT     High           Treatment      10 mg td                                                                                             5 days          Competent     Out       Unclear

  Hedrick^36^\                1998-1999     RCT     High           Treatment      10 mg td                                                                                             5 days          Competent     Out       Children

  Ambrozaitis^29^\            1997-2000     RCT     High           Prophylactic   10 mg td                                                                                             14 days         Competent     In        Adults

  Gravenstein^32^\            1997-2000     RCT     High           Prophylactic   10 mg td                                                                                             14 days         Competent     In        Adults

  Hayden(1)^34^\              1999-2000     RCT     High           Prophylactic   10 mg td                                                                                             10 days         Competent     Out       Adults

  ***Peramivir study***                                                                                                                                                                                                        

  Barosso(a)^30^              1999-2000     RCT     High           Treatment      100, 200, or 400 mg qd, or 200 md q12 h                                                              5 days          Competent     Out       Adults

  Barosso(b)^30^              1999-2000     RCT     High           Treatment      800 mg qd(day1) then400 mg q24 or 400 mg q24                                                         5 days          Competent     Out       Adults

  Barosso(c)^30^              1999-2000     RCT     High           Treatment      50, 200, or 400 mg qd                                                                                5 days          Competent     Out       Adults

  Barosso(d)^30^              1999-2000     RCT     High           Treatment      200, 400 or 800 mg                                                                                   5 days          Competent     Out       Adults

  ***Oseltamivir studies***                                                                                                                                                                                                    

  Whitley^38^                 1998-1999     RCT     High           Treatment      2 mg/kg twice daily (max 100 mg/day)                                                                 5 days          Competent     Out       Children

  Hayden(2)^35^\              2000-2001     RCT     High           Prophylactic   75 mg once daily                                                                                     10 days         Competent     Out       Mix

  Hayden(3-a)^33^\            2000          RCT     High           Treatment      75 mg/150 mg once/twice daily                                                                        5 days          Competent     Out       Adult

  Hayden (3-b)^33^            2000          RCT     High           Treatment      75 mg once daily                                                                                     5 days          Competent     Out       Adult

  Hayden (3-c)^33^            2000          RCT     High           Prophylactic   75 mg once daily                                                                                     7 days          Competent     Out       Adult

  Ison^37^                    Before 2009   RCT     High           Prophylactic   75 mg orally or suspension once daily for age = \> 13, weight-based or suspension for age \< 13      12 days         Compromised   In        Unclear

  Kiso^15^                    2002-2003     OBS     6/6            Treatment      4 mg/kg                                                                                              2-5 days        Competent     Mix       Children

  Kawai^42^                   2003-2004     OBS     6/6            Treatment      75 mg twice daily for adults and children \> 35 kg, weight-based twice daily for children \< 35 kg   5 days          Unclear       Out       Mix

  Hatekayama^41^              2004-2005     OBS     5/6            Treatment      Unclear                                                                                              Unclear         Mix           Unclear   Children

  Stephenson^43^              2005-2007     OBS     6/6            Treatment      Twice daily weight-based dosing regimen                                                              5 days          Competent     Unclear   Mix

  Cost^39^                    2009          OBS     4/6            Prophylactic   Unclear                                                                                              Unclear         Compromised   In        Children

  Harvala^40^                 2009          OBS     6/6            Treatment      Unclear                                                                                              Unclear         Mix           Unclear   Unclear

  Tramontana^44^              2009          OBS     6/6            Treatment      Varied across patients                                                                               Up to 43 days   Compromised   In        Adults

  Wang^45^                    2009          OBS     6/6            Treatment      Unclear                                                                                              Unclear         Mix           In        mix

  Winzer^46^                  2009          OBS     5/6            Treatment      Unclear                                                                                              Unclear         Unclear       Unclear   mix
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Study design is either a randomized clinical trial (RCT) or an observational study (OBS)

\*\*Quality scores for RCTs range from 1 to 4. Study scores for OBSs range from 1 to 6. Low scores indicate low quality, high scores indicate high quality.

Primary objective - estimating incidence
----------------------------------------

Most studies included a mix of the considered subgroups but did report results separately for each subgroup. It was therefore only possible to extract data from five studies for our primary objective: incidence of resistance among adult immunocompetent out-patients \[[@B27]-[@B31]\]. Among these five studies, one reported incidence of antiviral resistance associated with oseltamivir, three reported incidences of antiviral resistance associated with zanamivir, and one reported incidences of antiviral resistance associated with peramivir. In all five studies, patient recruitment ended in or before year 2000. Incidence of resistance was 0% in all five studies \[[@B27]-[@B31]\]. For this reason we did not produce a forest plot.

Secondary objective - incidence across subgroups
------------------------------------------------

Figure [2](#F2){ref-type="fig"} shows the incidence of antiviral resistance subgrouped by NAI (oseltamivir, zanamivir, and peramivir). The pooled incidence rate for oseltamivir was 2.6% (95%CI 0.7% to 5.5%). However, the estimated heterogeneity was I^2^= 90%. The incidence rate for all zanamivir studies was 0%. All zanamivir studies were RCTs. Further, all zanamivir studies ended in or before year 2000. Only one study measured incidence of antiviral resistance among subjects given peramivir and was reported to be 0%.

![**Forest plots of antiviral resistance incidence among oseltamivir studies subgrouped by neuraminidase inhibitor**. The numerator is the number of patients who developed resistance, and the denominator is the number of patients that received an NAI.](1471-2334-11-134-2){#F2}

Because antiviral resistance was only observed in oseltamivir studies, we did not produce subgroup forest plots including zanamivir or peramivir studies. Figure [3](#F3){ref-type="fig"} presents the forest plot of incidence of antiviral resistance to oseltamivir subgrouped by influenza type. The remaining subgroup forest plots of incidence of antiviral resistance are presented in additional files [1](#S1){ref-type="supplementary-material"}, [2](#S2){ref-type="supplementary-material"}, [3](#S3){ref-type="supplementary-material"}, [4](#S4){ref-type="supplementary-material"} and [5](#S5){ref-type="supplementary-material"} (figures A.1 to A.5).

![**Forest plots of antiviral resistance incidence among oseltamivir studies subgrouped by type of influenza**. The numerator is the number of patients who developed resistance, and the denominator is the number of patients that received an NAI.](1471-2334-11-134-3){#F3}

Antiviral resistance was observed among A/H1N1 patients in 5 of 6 studies with incidence rates varying from 3.6% and 27.3%. Among influenza A/H3N2 patients, incidence rates across three studies were 0%, 3.3%, 18%. Incidence rates among influenza B patients were 0% in two studies and 2% in one study (see figure [3](#F3){ref-type="fig"}). Antiviral resistance rates in prophylaxis studies were either 0% or low (4%), whereas more than half of the treatment studies reported resistance rates above 5% (see additional file [1](#S1){ref-type="supplementary-material"}, figure A.1).

Our subgroup analyses on RCTs versus observational studies, immunocompetent versus immunocompromised, out-patients versus in-patients, and adults versus children did not yield any apparent differences between subgroups. The lack of apparent differences was, in part, due to the large degree of heterogeneity within subgroups. All remaining subgroup analyses are presented in the appendices (see additional files [2](#S2){ref-type="supplementary-material"}, [3](#S3){ref-type="supplementary-material"}, [4](#S4){ref-type="supplementary-material"} and [5](#S5){ref-type="supplementary-material"} (figures A.2-A.5)).

Secondary objective - consequences of antiviral resistance
----------------------------------------------------------

Figure [4](#F4){ref-type="fig"} shows the forest plot of risk ratios for association between oseltamivir resistance and clinical complications that were reported in more than one study. The meta-analysis of the association between oseltamivir-resistance and pneumonia yielded a statistically significant risk ratio (RR 4.16, 95% CI 1.28 to 13.1, p = 0.02). The meta-analyses of the association with otitis yielded a pooled risk ratio of 0.97 (95% CI 0.41 to 2.43). The meta-analysis of the association with hospitalization yielded a pooled risk ratio of 0.60 (95% CI 0.24 to 1.48). The study by Hauge additionally reported adjusted risk ratios for the associations with sinusitis (RR 1.7, 95% CI 0.4 to 7.5) and with bronchitis (RR 0.8, 95% CI 0.4 to 1.8)\[[@B47]\]. Two deaths were reported in the study by Dharan \[[@B48]\]. However, these two patients died before they were admitted to the hospital. No deaths were reported in the other three identified association studies.

![**Forest plots of risk ratios for associations between antiviral resistance and clinical complications**. The risk ratios from the studies by Hauge and Ciancio are adjusted risk ratios obtained from multivariable models. The risk ratios from the Buchholz study are crude risk ratios based on zero-event continuity correction of 0.5. The Dharan risk ratio was transformed from an adjusted odds ratio based on a multivariable model.](1471-2334-11-134-4){#F4}

The meta-analyses of associations between oseltamivir resistance and the clinical symptoms (cough, fever, sore throat, myalgia, acute/sudden onset, runny nose and headache), did not reveal any differences between oseltamivir-resistant and oseltamivir-susceptible patients. All pooled risk ratio estimates were equal or very close to 1.00 and all 95% CIs included 1.00. The forest plots for these meta-analyses are presented in additional file [6](#S6){ref-type="supplementary-material"} and [7](#S7){ref-type="supplementary-material"} (figure A.6). One study (Dharan) additionally reported odds ratios on chills and breathing difficulty \[[@B48]\]. Risk ratio estimates for these two symptoms were close to 1.00 and had wide confidence intervals.

Table [2](#T2){ref-type="table"} provides a summary of the duration of illness reported across association and incidence studies. Overall, the oseltamivir-resistant and oseltamivir-susceptible patients seem to require the same number of days to reach resolution of symptoms.

###### 

Summary of symptoms and days to resolution of symptoms reported across association studies and incidence studies

  ------------------------------------------------------------------------------------------------------------------------------------
  Study                       Resistant patients   Sensitive patients                       
  --------------------------- -------------------- ----------------------------------- ---- ------------------------------------------
  ***Association studies***                                                                 

  *Buchholz (2009)^48^*       11                   Duration of sick leave:\            26   Duration of sick leave:\
                                                   Median: 7 days\                          Median: 7 days\
                                                   IQR: 6 to 14                             IQR: 7 to 10

  *Buchholz (2009)^48^*       38                   Days confined to bed:\              93   Days confined to bed:\
                                                   Median: 3.5 days\                        Median: 3 days\
                                                   IQR: 2 to 7                              IQR: 2 to 5

  *Dharan (2009)^50^*         49                   Activities limited: 1-7 days\       97   Activities limited: 1-30 days\
                                                   Median: 4 days                           Median: 4 days

  *Dharan (2009)^50^*         38                   Missed work or school: 1-10 days\   97   Missed work or school: 1-30 days\
                                                   Median: 4 days                           Median: 4 days

  ***Incidence studies***                                                                   

  *Kiso (2004)^15^*           9                    Duration of fever: 2-7 days\        41   Duration of fever: 1-6 days\
                                                   Median = 3 days                          Median = 3 days

  *Hatakeyama (2007)^41^*     1                    Duration of fever: 2 days           76   Mean duration of fever: 2.4 days

  *Stephenson (2009)^43^*     4                    Duration of fever: 5-6 days\        60   Authors commented no difference observed
                                                   Full recovery after: 9-10 days           

                                                                                            between resistant and sensitive patients
  ------------------------------------------------------------------------------------------------------------------------------------

The identified case reports showed a wide spectrum of complications associated with antiviral resistance. Table [3](#T3){ref-type="table"} summarized these complications in relation to the type of treatment, patient group and influenza. The complications associated with antiviral resistance were typically of a respiratory nature. Prolonged fever was also common. In 9 case reports, oseltamivir resistant patients were switched to zanamivir once viral resistance had been detected. In some cases, patients seemed to recover as a result of the switch, in others cases they did not.

###### 

Summary of patient and treatment characteristics, and complications believed to be associated with antiviral resistance in the reviewed case reports

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                          Period      Flu type   Mutation                      Proph/ Treat    Competent/ Compromised   In/Out Patient   Age     Days to resistance detection   Complications associated with resistance
  ------------------------------ ----------- ---------- ----------------------------- --------------- ------------------------ ---------------- ------- ------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ***Oseltamivir resistance***                                                                                                                                                         

  Baz^52^                        2005-2006   H3N2       E596G\                        Treat           Compromised              In               4 m     14                             Respiratory complications, prolonged viral shedding (about 90 days)
                                                        E119V\                                                                                                                         
                                                        I222V\                                                                                                                         
                                                        I223V                                                                                                                          

  Baz^52^                        2009        H1N1       H275Y                         Postexp Proph   Competent                Out              59y     8                              None. Recovered after 2 weeks

  Campanini^55^                  2009        H3N2       H274Y                         Treat           Compromised              In               2y      18                             42 days to resolution of flu symptoms

  Cane^56^                       2010        H1N1       H275Y                         Treat           Compromised              In               3y      NA                             1 month to resolution of flu symptoms

  CDC-Weekly(1)^57^              2009        H1N1       H275Y\                        Proph           Competent                Out              Teens   27                             None (\"uneventful recovery\")
                                                        I223V                                                                                                                          

  CDC-Weekly(1)^57^              2009        H1N1       H275Y\                        Proph           Competent                Out              Teens   14                             None (\"uneventful recovery\")
                                                        I223V                                                                                                                          

  CDC-Weekly(2)^48^              2009        H1N1       H275Y                         Treat           Compromised              In               Teens   30                             2 months to recovery

  CDC-Weekly(2)^48^              2009        H1N1       H275Y                         Treat           Compromised              In               40y     30                             2 months to revovery, prolonged neutron-penia and protracted bone marrow recovery, neutropenic fever, coagulase-negative Staphylococcus bacteremia, and Pneumocystis

  Couturier(1)^59^               2009        H1N1       H275Y                         Treat           Compromised              In               69y     9                              Renal function declined. Died after 17 days.

  Couturier(2)^59^               2009        H1N1       H275Y                         Treat           Compromised              In               66y     21                             Recovered after 1 month. Caught fever again after 3 months and died.

  Couturier(3)^59^               2009        H1N1       H275Y                         Proph           Competent                Out              36y     NA                             None

  De Jong^54^                    2005        H5N1       H274Y                         Treat           Competent                In               13y     5                              Patient died. Suffered from hypoxia and pneumonia

  Dulek^60^                      2009        H1N1       H275Y                         Treat           Compromised              In               18 m    22                             52 days of viral shedding, progressive pulmonary disease

  Gaur^61^                       2009        H1N1       H275Y                         Treat           Compromised              In               10y     14                             None reported

  Glikman^62^                    2009        H1N1       H275Y                         Treat           Compromised              In               11y     13                             Prolonged fever (\> 21 days)

  Hill-Cawthorne^63^             2009        H1N1       H275Y                         Treat           Compromised              Out              56y     20                             Prolonged fever and cough (2 months)

  Ison(1)^64^                    2001        NA         Asp198Asn\                    Proph           Compromised              In               2y      42                             Continued rhinorrhea and dry cough, progressive respitatory distress, gastrointestinal bleeding. Eventually died.
                                                        Aer285Ala                                                                                                                      

  Ison(2)^64^                    2002        H3N2       Arg142Gly\                    Treat           Compromised              In               63y     90                             Prolonged cough and nasal congestion
                                                        Tyr195Phe                                                                                                                      

  Ison(3)^64^                    2003        H3N2       Glu119Val\                    Treat           Compromised              In               60y     NA                             Progressive respiratory compromise and pneumonia, continued respiratory failure. Died of haemorrhagic stroke.
                                                        Ser31Asn                                                                                                                       

  Le^53^                         2005        N5N1       H274Y                         Both            Competent                Out              14y     4                              None. Recovered after 2 weeks.

  Memoli^65^                     2009        H1N1       Amino-acid position 245-248   Treat           Compromised              In               43y     5                              None. Recovered after 2 weeks.

  Nguyen\*\*^66^                 2009        H1N1       H27Y                          Treat           Compromised              In               14y     17                             Died of complications after 2 months

                                                        I223R                                                                                                                          

  Rousset\*\*^67^                2009        H1N1       H275Y                         Treat           Compromised              In               24y     6                              Patient died at day 140

  Speers^68^                     2009        H1N1       H275Y                         Treat           Compromised              In               38y     3                              None. Eventually died

  Thabet^69^                     2009        H1N1       H274Y                         Treat           Compromised              In               3y      10                             None reported.

  Van der Vries\*^70^            2009        H1N1       H275Y                         Treat           Compromised              In               5y      7                              Resolutions of symptoms after 3 months

  ***Zanamivir resistance***                                                                                                                                                           

  Gubareva^16^                   1998        NA         152Argr-Lys                   Treat           Compromised              In               18 m    8                              Not resolved, patients died.

  Van der Vries\*^70^            2009        H1N1       I223R                         Treat           Compromised              In               5y      56                             Resolutions of symptoms after 3 months
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* patient was treated with oseltamivir first, zanamivir second, and developed resistance to both antivirals

\*\* patient also had reduced sensitivity to zanamivir

Discussion
==========

The primary focus of this review was to describe the incidence of resistance to oseltamivir, zanamivir, and peramivir in adult immunocompetent outpatients for the prevention and treatment of influenza. However, we did not identify sufficient evidence to draw any conclusions about this issue. The secondary focus of our review was to describe the incidence and consequences of antiviral resistance across various population groups. Overall the incidence of oseltamivir-resistance across studies was 2%. We found higher oseltamivir-resistance incidence rates among influenza A patients - particularly those of the H1N1 subtype. Zanamivir was associated with 0% incidence of resistance. Only one study measured incidence of antiviral resistance among subjects given peramivir and it was reported to be 0%. However, zanamivir and peramivir clinical trials stopped enrolling in year 2000 at the latest, and therefore have little generalizability. We did not compare the incidence rates between drugs because there are no head-to-head studies that have compared these drugs. Our analyses of consequences associated with development of antiviral resistance demonstrated that oseltamivir-resistant patients are approximately 4 times more likely to suffer from pneumonia than oseltamivir-susceptible patients. We did not find any associations between oseltamivir-resistance and other clinical complications or symptoms. We did not identify any studies reporting on association between zanamivir or peramivir resistance and clinical complications or symptoms. Our review of case reports shows that antiviral resistance can be associated with a number of serious complications. Such complications are typically of a respiratory nature and may in some cases be so severe that the patient will die, but whether it depends on viral resistance or on the host\'s immune response needs to be determined.

Our review comes with a number of strengths and limitations. We collectively reviewed randomized clinical trials, cohort studies, case series, and case reports. Randomized clinical trials are typically conducted under controlled settings that may not be entirely representative of general clinical practice. In the context of our review, such controlled settings may substantially reduce the risk of developing antiviral resistance. By including observational studies in our review, we obtain incidence estimates that are generalizable to conventional clinical practice settings. Furthermore, our additional inclusion of case reports allowed us to evaluate the severity of the clinical complications that can arise from antiviral resistance.

Despite including a wide range of considered study designs, our review finds its limitations in the paucity of evidence. We did not find any recent studies that investigated incidence of antiviral resistance associated with zanamivir or peramivir, in fact, all studies on zanamivir ended patients\' recruitment in 2000 at the latest. Thus, we were unable to assess whether zanamivir and peramivir still yields a (close to) 0% incidence of antiviral resistance. In addition to the time factor, it is reported that there is a cross-resistance association between oseltamivir and peramivir \[[@B49],[@B69]\]. For patients infected with A/H1N1 virus harboring the H275Y mutation, studies conducted before the 2007-2009 seasons are therefore likely to underestimate resistance to peramivir dramatically. Furthermore, recent peramivir clinical trials have evaluated a parenteral injection form instead of prior oral tablets \[[@B28],[@B70]\].

Most oseltamivir studies included a mix of population subgroups and had little or no reporting on subgroup results. As a result, much within-subgroup heterogeneity ensued, and thus, many of our subgroup analyses did not yield any \'apparent\' differences. The presence of a mixture of resistant and susceptible viruses especially in immunocompromised hosts may also potentially complicate the interpretation of our findings. Lastly, we did not find any studies on incidence of antiviral resistance among H5N1 patients, and only two case reports on H5N1 patients \[[@B51],[@B52]\]. As for case reports, it is likely that our search may have missed a substantial number of case reports due to such publications being poorly indexed in the utilized search engines. We excluded some case reports of oseltamivir resistance in H5N1 infected humans because no clinical data was reported \[[@B71]\] or because resistance was detected pre-therapy \[[@B72]\].

The rates at which pneumonia occurred in oseltamivir-susceptible patients were between 1% and 3%\[[@B45]-[@B48]\]. Meanwhile, our meta-analysis suggests that oseltamivir-resistant patients are 4-times more likely to suffer from pneumonia. Assuming that 2% of oseltamivir-susceptible patients suffer from pneumonia, 1 out of every 50 oseltamivir-susceptible patients would suffer from pneumonia in comparison to 1 out of every 12 oseltamivir-resistant patients. It is noteworthy that in the identified case reports, many cases of resistance arose in immunocompromised patients adding a confounder in the interpretation of this association.

Our review provides valuable insight on the incidence of antiviral resistance associated with oseltamivir use. However, we were not able to draw inferences about incidence of antiviral resistance associated with zanamivir or peramivir use due to the absence of recent studies on the topic. The reviewed case reports mainly involved immunocompromised subjects who were hospitalized (in-patients) and received oseltamivir as treatment rather than prophylaxis. This could suggest a tendency that notable complications associated with antiviral resistance more frequently arise among such patients. To confirm this, however, future cohort studies that investigate the associations between antiviral resistance and complications should incorporate patient and treatment characteristics in the multivariate models.

Conclusion
==========

Our results demonstrate that that a substantial number of patients may become oseltamivir-resistant as a result of oseltamivir use, and that oseltamivir resistance may be significantly associated with pneumonia. In contrast, zanamivir resistance has been rarely reported to date.
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###### Additional file 1

**Additional figure 1 (Figure A.1)**. Forest plots of antiviral resistance incidence among oseltamivir studies subgrouped by study design. The numerator is the number of patients who developed resistance, and the denominator is the number of patients that received an NAI.
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###### Additional file 2

**Additional figure 2 (Figure A.2)**. Forest plots of antiviral resistance incidence among oseltamivir studies subgrouped by immunocompetent and immunocompromised patients. The numerator is the number of patients who developed resistance, and the denominator is the number of patients that received an NAI.
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###### Additional file 3

**Additional figure 3 (Figure A.3)**. Forest plots of antiviral resistance incidence among oseltamivir studies subgrouped by out-patients and in-patients. The numerator is the number of patients who developed resistance, and the denominator is the number of patients that received an NAI.

###### 

Click here for file

###### Additional file 4

**Additional figure 4 (Figure A.4)**. Forest plots of antiviral resistance incidence among oseltamivir studies subgrouped by study age group (adults or children). The numerator is the number of patients who developed resistance, and the denominator is the number of patients that received an NAI.
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###### Additional file 5

**Additional figure 5 (Figure A.5)**. Forest plots of antiviral resistance incidence among oseltamivir studies subgrouped by intervention purpose. The numerator is the number of patients who developed resistance, and the denominator is the number of patients that received an NAI.
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###### Additional file 6

**Additional figure 6 (Figure A.6)**. Forest plots of risk ratios for associations between antiviral resistance and clinical symptoms. All risk ratio estimates are crude estimates
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###### Additional file 7

**Additional figure 6 (Figure A.6)**. Forest plots of risk ratios for associations between antiviral resistance and clinical symptoms. All risk ratio estimates are crude estimates
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